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confounding in mediation
investigations
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Abstract
Background: Random allocation avoids confounding bias when estimating the average treatment effect. For continuous
outcomes measured at post-treatment as well as prior to randomisation (baseline), analyses based on (A) post-
treatment outcome alone, (B) change scores over the treatment phase or (C) conditioning on baseline values (analysis
of covariance) provide unbiased estimators of the average treatment effect. The decision to include baseline values of
the clinical outcome in the analysis is based on precision arguments, with analysis of covariance known to be most pre-
cise. Investigators increasingly carry out explanatory analyses to decompose total treatment effects into components
that are mediated by an intermediate continuous outcome and a non-mediated part. Traditional mediation analysis might
be performed based on (A) post-treatment values of the intermediate and clinical outcomes alone, (B) respective change
scores or (C) conditioning on baseline measures of both intermediate and clinical outcomes.
Methods: Using causal diagrams and Monte Carlo simulation, we investigated the performance of the three competing
mediation approaches. We considered a data generating model that included three possible confounding processes
involving baseline variables: The first two processes modelled baseline measures of the clinical variable or the intermedi-
ate variable as common causes of post-treatment measures of these two variables. The third process allowed the two
baseline variables themselves to be correlated due to past common causes. We compared the analysis models implied
by the competing mediation approaches with this data generating model to hypothesise likely biases in estimators, and
tested these in a simulation study. We applied the methods to a randomised trial of pragmatic rehabilitation in patients
with chronic fatigue syndrome, which examined the role of limiting activities as a mediator.
Results: Estimates of causal mediation effects derived by approach (A) will be biased if one of the three processes
involving baseline measures of intermediate or clinical outcomes is operating. Necessary assumptions for the change
score approach (B) to provide unbiased estimates under either process include the independence of baseline measures
and change scores of the intermediate variable. Finally, estimates provided by the analysis of covariance approach (C)
were found to be unbiased under all the three processes considered here. When applied to the example, there was evi-
dence of mediation under all methods but the estimate of the indirect effect depended on the approach used with the
proportion mediated varying from 57% to 86%.
Conclusion: Trialists planning mediation analyses should measure baseline values of putative mediators as well as of con-
tinuous clinical outcomes. An analysis of covariance approach is recommended to avoid potential biases due to confound-
ing processes involving baseline measures of intermediate or clinical outcomes, and not simply for increased precision.
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Introduction
There exists an extensive literature on how to handle
baseline measures of a continuous clinical outcome
variable in randomised controlled trials (RCTs). This
literature relates to estimating the total treatment effect
in terms of the clinical outcome.1–4 Mediation investi-
gations that partition total intervention effects into
mediated and non-mediated components have become
increasingly popular, in particular in trials of mental
health interventions such as psychological therapies.
The UK National Institute for Health Research and
the Medical Research Council fund the Efficacy and
Mechanism Evaluation programme, which has as one
of its aims understanding treatment mechanisms – in
our view, ideally evaluated using an appropriate and
valid analysis of mediation. But little advice is available
on how to deal with baseline measures when attempt-
ing such mediation analyses, or indeed whether baseline
measurement of clinical and putative mediator out-
comes is necessary. This article is focused on compar-
ing approaches for dealing with baseline measures of
outcomes when total treatment effect estimation is to
be supplemented by mediation assessment in trials.
Intention-to-treat analyses aim to evaluate the effect
of treatment offer (effectiveness) or treatment receipt
(efficacy, assuming full compliance with treatment offer).
There are three well-known approaches for estimating
this total treatment effect when the clinical outcome has
also been measured before randomisation (baseline):
(A) Post approach: compare post-treatment clinical
outcomes between trial arms.
(B) Change score approach: construct change scores
by subtracting baseline values from the post-
treatment values and compare the change
scores between trial arms.
(C) Analysis of covariance (ANCOVA) approach:
estimate the trial arm difference from a regres-
sion model that contains baseline measures of
the outcome as a covariate, and models a linear
effect of the baseline measure on post-treatment
outcome.
The three intention-to-treat estimators are from a
wider class of unbiased baseline adjusted estimators.
Under a linear model the best adjustment is achieved
by ANCOVA and so approach (C) is the most precise
estimator.1–4
Trials of psychological therapies increasingly supple-
ment total treatment effect estimation by a mediation
analysis.5–9 The development of a psychological therapy is
typically based on a theory regarding modifiable target
factors and it is of interest to assess empirically how much
of the total intervention effect can be attributed to changes
in such a target intermediate outcome (an indirect effect).
On occasions, it can also be of interest to demonstrate that
an effect does not only come about by changing an inter-
mediate variable (e.g. by changing adherence with medica-
tion), that is, to show a direct effect.
The traditional Baron and Kenny10 steps for media-
tion assessment fit three regression models: (1) a regres-
sion model describing the treatment effect on the
clinical outcome, (2) a regression model describing the
treatment effect on the intermediate outcome and (3) a
regression model describing the joint effects of the
intermediate variable and the treatment on the clinical
outcome. Traditionally, none of these models contain
interactions between treatment and baseline variables
nor do models (1) or (3) contain an interaction between
treatment and the intermediate variable. Inferences
regarding indirect and direct treatment effects can be
obtained by fitting two of these regression models. We
focus on fitting models (2) and (3) which is more pro-
minent in the behavioural/social sciences. Trialists
again have three choices for incorporating baseline
measures:
(A) Post approach for mediation. Use the intermedi-
ate outcome as the dependent variable for
model (2); use the clinical outcome as the
dependent and the intermediate outcome as an
explanatory variable for model (3); ignore the
baseline measures.
(B) Change score approach for mediation. Use
change in the intermediate variable as the
dependent variable for model (2); use change in
the clinical outcome as the dependent and
change in the intermediate outcome as an
explanatory variable for model (3).
(C) ANCOVA approach for mediation: Use the
intermediate outcome as the dependent variable
for model (2); use the clinical outcome as the
dependent and the intermediate outcome as an
explanatory variable for model (3); include base-
line measures of both variables in both models.
To our knowledge, there exists little advice as to how
to choose between these competing approaches and the
practitioner might be forgiven for thinking that this is
solely a matter of precision, as is the case for total
effects. In this article, we demonstrate that despite ran-
domisation such arguments are too simplistic for med-
iation investigations. Indeed, we conclude that
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measurement of baseline variables and subsequent
incorporation into analysis models is necessary to avoid
particular biases in estimators of causal mediation
effects, and end up recommending approach (C) on the
grounds of bias reduction.
Methods
Causal treatment effects
We consider trials that have observed a continuous
putative mediator variable and a continuous clinical
outcome at baseline (t= 0) and at a post-randomisation
time point. We focus on the scenario where the assess-
ment time point of the mediator (t= 1) precedes that of
the clinical outcome (t= 2) as such time separation sup-
ports the theory of a temporal causal chain from treat-
ment to mediator to clinical outcome.11,12
We observe the following variables for trial partici-
pants i 2 f1, . . . , ng:
 Ri is the treatment offered to participant i with pos-
sible values r= 0 for being allocated to the control
arm and r= 1 for the therapy arm.
 Mi, 0 and Mi, 1 are the values measured on the puta-
tive mediator variable for participant i at t= 0 and
t= 1, respectively.
 Yi, 0 and Yi, 2 are the values measured on the clinical
outcome variable for participant i at t= 0 and
t= 2 respectively.
We consider potential outcomes13 for individuals from
the trial’s target population:
 Mi, 1(R= r)=Mi, 1(r) the intermediate outcome that
would have been observed at t= 1 if individual i
had been allocated to trial arm r.
 Yi, 2(R= r)= Yi, 2(r) the clinical outcome that would
have been observed at t= 2 if individual i had been
allocated to trial arm r.
 Yi, 2(R= r,M1=m)= Yi, 2(r,m) the clinical outcome
that would have been observed at t= 2 if individual
i had been allocated to trial arm r and the inter-
mediate outcome had been set to value m.
This allows us to define a causal individual treatment
(offer) effect in terms of the clinical outcome as the
contrast
Di :¼ Yi, 2 1ð Þ  Yi, 2 0ð Þ
and the causal average treatment (offer) effect in the
trial’s target population as
ATEY :¼ED Dið Þ
ATEY is an estimand quantifying the total treatment
effect. Following the work of VanderWeele and his
colleague,14,15 we define an individual natural direct
treatment (offer) effect as
Fi :¼ Yi, 2 1,Mi, 1 0ð Þ½   Yi, 2 0,Mi, 1 0ð Þ½ 
and the individual natural indirect treatment (offer)
effect as
Ci :¼ Yi, 2 1,Mi, 1 1ð Þ½   Yi, 2 1,Mi, 1 0ð Þ½ 
This leads to definitions of a causal (average) natural
direct treatment (offer) effect as
NDE :¼EH Fið Þ
and a causal (average) natural indirect treatment (offer)
effect as
NIE :¼EC Cið Þ
so that ATEY =NDE+NIE holds in the continuous
case. Importantly, the natural direct effect (NDE) and
the natural indirect effect (NIE) represent total treatment
effect components that have causal interpretations.
These causal mediation estimands can be expressed
as functions of parameters of structural models. Let
denote a the effect of changing treatment offer in a lin-
ear structural model for M1(r). Then the average treat-
ment effect with respect to the intermediate variable
ATEM :¼ E½Mi, 1(1)Mi, 1(0), which we term the target
effect, is ATEM =a. Furthermore, let g be the effect of
changing treatment offer and b the effect of increasing
the value of the mediator variable by one unit in a lin-
ear structural model for Y2(r,m) that does not contain
an interaction between treatment and mediator. Then it
follows that NDE= g and NIE=ab.16 Under sequen-
tial ignorability, linearity and no-interactions assump-
tions causal mediation analysis can be performed by
targeting model parameters a,b and g and using the
product of coefficient method.17
Causal mediation analysis in trials
We turn our attention to understanding how baseline
variables M0 or Y0 should be incorporated into regres-
sion models when the natural direct and indirect effects
as well as the intention-to-treat effect are of interest.
We start by considering what might be a realistic data
generating model for trial outcomes. Then we describe
the analysis models that would be assumed by the com-
peting mediation analysis approaches and contrast
them with the true data generating model to assess their
potential for producing biased estimates. Finally, we
confirm our bias predictions by means of a Monte
Carlo simulation study.
We will employ linear structural equation modelling
diagrams to describe models graphically. The resulting
linear structural model equations are straightforward
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to read from these graphs. Briefly, observed variables
are indicated by square boxes and unobserved variables
by circles. A single-headed arrow represents a causal
effect of one variable on another and the associated
path coefficient has a causal interpretation. A double-
headed arrow indicates an un-modelled correlation
between two variables. Importantly, the absence of an
unblocked path connecting two variables reflects an
independence assumption; for more details including
path tracing rules see study by Pearl18 or Spirtes et al.19
Data generating model for trial outcomes
Figure 1 represents a realistic data generating model for
RCTs. It is a simple change score model for longitudinal
data: Baseline measures on the left-hand side are mea-
sured first (R, M0 and Y0), followed by the mediator at
the first post-randomisation assessment time point, M1,
and the clinical outcome at the second time point, Y2, at
the right-hand side. The characteristic feature of the
change score model is that variables measured at earlier
time points affect variables at later time points by driv-
ing their change over the relevant time periods.20 Thus,
in our trials context baseline measures and treatment
can cause change in the mediator or the clinical out-
come (M1 M0 and Y2  Y0, respectively). In addition,
the level of the post-randomisation mediator M1 can
cause change in the clinical outcome. Mediation occurs
if treatment offer (R) has a causal effect on the change
score M1 M0 and so also on M1 (target effect a), and
M1 has a causal effect on Y2  Y0 and so also on Y2
(path coefficient b). Under this change score model the
NIE is given by the product ab and the non-mediated
(natural direct) effect is the path coefficient g. (Some
path coefficients in Figure 1 have been fixed at the value
‘1’ to ensure that a participant’s score on a variable
measured at a post-randomisation time point is the sum
of the participant’s baseline and change scores.)
Importantly, Figure 1 includes three processes
involving baseline measures of outcomes (indicated by
dashed paths).
 M0 observed common cause of intermediate and clini-
cal outcome: Baseline measures of the putative med-
iator drive M1 (directly by determining its level or
indirectly by affecting changes over the follow-up
period, path coefficient c1) as well as Y2 (by affect-
ing changes over the longer follow-up period, path
coefficient c2).
 Y0 observed common cause of intermediate and
clinical outcome: Baseline measures of the clinical
outcome drive Y2 (directly by determining its level
or indirectly by affecting changes, path coefficient
d1) as well as M1 (by affecting changes, path coeffi-
cient d2).
 V common cause of baseline levels: A past unob-
served variable V affects baseline levels of the med-
iator (path coefficient l1) and the outcome
(coefficient l2). (It does not affect R due to random
treatment offer allocation.) Since baseline measures
form part of the respective post-treatment
measures, V is a latent common cause of M1 as
well as Y2.
Each of these scenarios is plausible, in particular the
existence of V. The measures taken at baseline do not
represent the first occasion that the measures occur in
the individual, but instead represent the first occasion
that the investigators have observed the measures.
Therefore, it is reasonable to assume that something
Figure 1. Linear structural equation diagram describing a realistic data generating model for trials.
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has driven the values of M and Y at the first time they
are measured. In practice, there will be multiple factors
but we can represent these by a single unmeasured
latent construct V.
Predicted biases of causal mediation effect
estimators
We proceed to contrast the (true) data generating model
in Figure 1 with the analysis models assumed by the
three competing mediation approaches. These analy-
sis models are fully described by the structural equa-
tion diagrams shown in Figure 2. Importantly, the
diagrams in Figure 2 provide a graphical representa-
tion of the assumptions made by the various
approaches as absences of paths between variables
indicate independence assumptions. We can therefore
utilise these graphs to make predictions about scenar-
ios under which confounding biases might arise in
estimators of mediation effects.
Under each mediation analysis approach, the target
effect is estimated by the path coefficient labelled a in
the structural equation diagrams in Figure 2. Similarly,
the NDE is estimated by the path coefficient labelled g
in Figure 2. Finally, the NIE is estimated by construct-
ing the product of path coefficients labelled a and b,
with inferences for this product estimator often con-
structed by bootstrapping as sampling distributions can
be skewed.21
The analysis model in Figure 2(a) implies that there
are no paths connecting R andM1 other than the causal
effect of treatment offer. This model assumption agrees
with the data generating model in Figure 1 due to ran-
domisation in a trial. As a result, we predicted that the
target effect can be estimated without bias using the
post approach (A). This analysis model also assumes
that there are no paths connecting M1 and Y2 other
than the causal effect of the mediator. This model
assumption is not in agreement with the data generat-
ing model. Instead Figure 1 shows a number of possible
paths connecting M1 and Y2. For example, if c2 6¼ 0
then there exists a so-called backdoor path via M0. As
a result of these unaccounted backdoor paths, we pre-
dicted that parameters of the true structural model for
Y2 cannot be estimated without bias by approach A.
Consequently, estimators of both the natural direct and
indirect effects may suffer from confounding bias.
The analysis model in Figure 2(b) implies that there
are no paths connecting R and M1 M0 other than the
causal effect of treatment offer. This model assumption
agrees with the data generating model in Figure 1 and
we predicted that the target effect can be estimated
without bias using the change score approach (B). This
analysis model also implies that there are no backdoor
paths connecting M1 M0 and Y2  Y0. This causal
model assumption is not generally in agreement with
the data generating model. Instead, Figure 1 shows a
number of possible paths connecting M1 M0 and
Y2  Y0. For example, if c1 6¼ 0 then there exists a back-
door path via M0. These paths only cease to exist if
some baseline measures are not predictive of subse-
quent changes. As a result, we predicted that estimators
of both natural direct and indirect effects may suffer
from confounding bias under approach (B).
The analysis model in Figure 2(c) assumes that all of
R, M0 and Y0 have causal effects on M1 and might be
correlated with each other. This analysis model includes
all the true causes of M1 and is more general than the
data generating model in that it leaves all the correla-
tions between the baseline variables to be freely esti-
mated. As a result, we predicted that the target effect
can be estimated without bias using the ANCOVA
approach (C). This analysis model also assumes that all
of M1, R, M0 and Y0 affect Y2. Again, all the true causes
of Y2 are included and we predicted that the natural
direct and indirect effects can be estimated without bias
by approach (C).
To validate our graphically derived bias predictions,
we considered six pertinent data generating models for
which we could make bias predictions. Table 1 sum-
marises these data generating models together with our
predictions. The models were chosen such that they
reflected each of the three potential confounding pro-
cesses (Models 1, 2 and 5 in Table 1). In addition, for
each confounding process a second model was included
that was subject to additional or altered parameter
restrictions, since we predicted that the change score
approach would perform favourably under these par-
ticular restrictions.
Results
Simulation study
Details of our simulation study design are provided in
the Supplementary Material. Briefly, we simulated out-
comes from a parallel group trial with n = 500 partici-
pants (250 per arm) under each of the six models
listed in Table 1. Monte Carlo simulation techniques
(s = 10,000 simulations) were used to evaluate the sta-
tistical properties of the three competing estimation
approaches.
Table 2 shows the bias results from the simulation
study. The expected values of the competing estimators
can be compared against the true estimand values to
assess bias:
 Target effect estimation: As expected all three esti-
mation approaches can estimate the target effect
without bias. The ANCOVA approach (C) was the
most precise across all data generating models. In
models where an effect of baseline measures on
change in the intermediate variable was assumed
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absent (c1= 0 in Models 2–6) the precision of the
change score estimator and the ANCOVA
estimator was comparable. This is because under
this assumption the true effect of the baseline
(a)
(b)
(c)
Figure 2. Linear structural equation diagrams describing the analysis models assumed by three approaches to mediation analysis:
(a) post approach, (b) change score approach and (c) ANCOVA approach.
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variable on the post-treatment measure is unity
(Figure 1).
 Causal mediation effects estimation: As expected,
approach (A) suffered bias in estimates of natural
Table 2. Bias results from simulation study: expected values of estimators based on s = 10,000 simulations.a
Process involving baseline
measures
Estimation
approach
True estimand value
ATEM = 0:5 NIE = 0.125 NDE = 0.375 ATEY = 0:5
Model 1: Only M0 observed
common cause
(A) 0.500 0.104 0.395 0.500
(B) 0.500 0.093 0.407 0.501
(C) 0.500 0.125 0.375 0.500
Model 2: Only Y0 observed
common cause
(A) 0.501 0.115 0.387 0.502
(B) 0.500 –0.062 0.563 0.500
(C) 0.500 0.125 0.375 0.501
Model 3: Only M0 observed
common cause and not
predictive of M1 M0
(A) 0.501 0.084 0.418 0.502
(B) 0.500 0.125 0.375 0.500
(C) 0.500 0.125 0.375 0.501
Model 4: Only Y0 observed
common cause and not
predictive of M1 M0
(A) 0.501 0.084 0.418 0.502
(B) 0.500 0.125 0.375 0.500
(C) 0.500 0.125 0.375 0.501
Model 5: Only V common
cause of baseline levels,
assuming M0 not predictive
of M1 M0 and Y0 not
predictive of Y2  Y0
(A) 0.500 0.248 0.253 0.502
(B) 0.500 0.148 0.352 0.500
(C) 0.500 0.125 0.375 0.500
Model 6: Only V common
cause of baseline levels,
assuming M0 not predictive
of M1 M0 and Y0 not
predictive of M1 M0
(A) 0.500 0.136 0.366 0.502
(B) 0.500 0.125 0.375 0.500
(C) 0.500 0.126 0.375 0.501
ATE: average treatment effect; NIE: natural indirect effect; NDE: natural direct effect.
Biased estimators are shown in italics.
aSimulations assumed that treatment effects or mediator effects did not vary between individuals (effect homogeneity).
Table 1. Bias predictions for three different estimators of causal mediation effects.a
Process involving baseline
measures
Parameter restrictions
in data generating
model (Figure 1)
(A) Post
approach
(B) Change
score approach
(C) ANCOVA
approach
Model 1: Only M0 observed
common cause
c1 6¼ 0; c2 6¼ 0
l2= 0; d2= 0
Biased Biased Asymptotically unbiased
Model 2: Only Y0 observed
common cause
d1 6¼ 0; d2 6¼ 0
l2= 0; c1= 0
Biased Biased Asymptotically unbiased
Model 3: Only M0 observed
common cause and not
predictive of M1 M0
c1= 0; c2 6¼ 0
l2= 0; d2= 0
Biased Asymptotically unbiased Asymptotically unbiased
Model 4: Only Y0 observed
common cause and not
predictive of M1 M0
d1 6¼ 0; d2= 0
l2= 0; c1= 0
Biased Asymptotically unbiased Asymptotically unbiased
Model 5: Only V common
cause of baseline levels,
assuming M0 not predictive
of M1 M0 and Y0 not
predictive of Y2  Y0
l1 6¼ 0; l2 6¼ 0
c1= 0; d1= 0
Biased Biased Asymptotically unbiased
Model 6: Only V common
cause of baseline levels,
assuming M0 not predictive
of M1 M0 and Y0 not
predictive of M1 M0
l1 6¼ 0; l2 6¼ 0
c1= 0; d2= 0
Biased Asymptotically unbiased Asymptotically unbiased
ANCOVA: analysis of covariance
aThe target effect can be estimated without bias by either approach. Biases refer to estimators of the natural direct and indirect effects.
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direct and indirect effects under all models.
Approach (B) was only able to provide unbiased
estimates of mediation effects under Models 3, 4
and 6. As predicted, for approach (B) not to suffer
from bias, a necessary assumption is the absence of
some effects of baseline measures on change scores.
In particular, these absences must be such that they
remove any backdoor paths connecting the media-
tor change score and the clinical outcome change
score. As predicted, approach (C) was able to pro-
vide unbiased estimates of mediation effects under
all models.
 Intention-to-treat effect estimation (clinical out-
come): All three estimation approaches were able
to estimate the average treatment effect on the clini-
cal outcome without bias. This suggests that respec-
tive biases in estimates of NIE and NDE cancel
each other out. Out of the three estimators consid-
ered here the ANCOVA approach (C) was the most
precise under all models.
Worked example in a randomised trial
The Fatigue Intervention by Nurses Evaluation (FINE)
trial (IRCTN74156610) was an RCT comparing prag-
matic rehabilitation with supportive listening, a non-
directive counselling treatment and treatment as usual
by the general practitioner for patients in primary care
with chronic fatigue syndrome/myalgic encephalomyeli-
tis or encephalitis. When the findings of the trial were
reported, pragmatic rehabilitation and supportive lis-
tening were each compared with treatment as usual in
an intention-to-treat analysis.22
Wearden and Emsley6 examined the potential med-
iators of the effect of pragmatic rehabilitation on
improvements in fatigue. The outcome was the Chalder
fatigue scale score at 70 weeks. Reduction in limiting
activities at 20 weeks was found to mediate the positive
effect of pragmatic rehabilitation on fatigue at
70 weeks. The focus here is on a secondary data analy-
sis of the trial data in order to illustrate the different
methods (A)–(C) for dealing with baseline variables in
the mediation analysis.
In the trial, 95 patients were randomised to prag-
matic rehabilitation and 100 to treatment as usual. We
analyse a complete-case dataset containing 146 patients
(70 in pragmatic rehabilitation and 76 in treatment as
usual), with observed data on seven variables: the out-
come (Chalder fatigue score, scored 0–33, high score
means more fatigue) at baseline and 70 weeks, the med-
iator (limiting activities, lower scores indicating more
adaptive behaviours) at baseline and 20 weeks, rando-
misation indicator and the stratification variables
(whether the patient was non-ambulatory (y/n) and
London myalgic encephalomyelitis criteria).
The analysis was conducted in Stata version 14.2
using the paramed command.12 Since we assume no
interactions and have continuous mediators and out-
comes, this produces the same estimates as a structural
equation modelling approach would. Note that this dif-
fers slightly from the analysis presented by Wearden
and Emsley,6 which also adjusted for other potential
mediators at baseline.
Table 3 shows the results of fitting the three analysis
models. For all the three methods, the intention-to-
treat result is statistically significant indicating that
pragmatic rehabilitation improves fatigue score relative
to treatment as usual and estimates vary from 22.76 to
23.25 points. All three estimators are valid with
approach (C) providing the most precise estimate. The
post approach (A) decomposes this into an NIE of
21.59, with 57% of the total effect mediated. The
change score approach (B) indicated that the indirect
effect accounted for 68% of the total effect. The
ANCOVA approach (C), which the simulations have
shown to be the unbiased estimator, gives an indirect
effect of 22.55 accounting for 86% of the total effect.
While approach (C) appears to remove bias, for the
NIE this comes at the price of standard error (SE)
inflation. However, the bias correction outweighs this
inflation. Consistent with the results of our supplemen-
tary simulation study for the NIE, the closed form of
the SEs is close to the bootstrap SEs for methods (A)
and (B), whereas for method (C) the closed form esti-
mated SE of 0.71 is an underestimate of the bootstrap
SE of 0.85.
For all the three approaches, the indirect effect is
statistically significant while the direct effect is not sig-
nificant. This indicates that there is mediation through
limiting activities. Qualitatively, the methods all give
this conclusion, but as the aim of mediation is to accu-
rately decompose the total effect into an indirect effect
and a direct effect, the methods give various estimates,
Table 3. Causal treatment effect estimates from the FINE trial ((standard errors in brackets).
Estimation approach Intention-to-treat effect Natural direct effect Natural indirect effect PM%
(A) 22.76 (1.27), p = 0.03 21.18 (1.28), p = 0.36 21.59 (0.57), p = 0.01 57
(B) 23.25 (1.30), p = 0.01 21.04 (1.33), p = 0.43 22.21 (0.68), p\ 0.01 68
(C) 22.98 (1.25), p = 0.02 20.43 (1.28), p = 0.74 22.55 (0.71), p\ 0.01 86
PM% is percentage of total effect mediated by natural indirect effect.
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and we conclude that method (C) provides the correct
estimate.
Discussion
We recommend that trialists measure baseline values of
putative mediator variables as well as the clinical out-
come when planning to conduct mediation investiga-
tions. Of the three mediation approaches considered
here, we recommend the ANCOVA approach which
includes baseline measures of the intermediate and clin-
ical variable as covariates in all regression models. It
was the only approach that was able to provide valid
estimates under all the scenarios that we considered.
Importantly, in contrast to total treatment effect esti-
mation, when partitioning effects into mediated and
non-mediated components, the decision for ANCOVA
is based on bias reduction rather than precision
arguments.
Mediation investigations based purely on post-
treatment measures of the putative mediator and clini-
cal outcome were found to suffer from bias under all
the processes involving baseline variables that we con-
sidered. Importantly, the change score approach, often
favoured by practitioners, only removes biases under
additional assumptions regarding independence of mea-
sures of baseline values and change over time. The mini-
mum assumptions necessary are that neither baseline
measures of the putative mediator nor of the clinical
variable predict change in the mediator variable. Such
predictive effects might be present due to baseline values
predicting illness trajectories. In addition, negative pre-
dictive effects of baseline levels on change in the same
variable might occur as a result of regression to the
mean, especially in populations that have been selected
as ‘severe’ on the basis of outcome variables that might
be subject to measurement error.23 Independence
assumptions have been questioned before (e.g. Gollob
and Reichardt24 or Cole and Maxwell11) and are
unlikely to hold in mental health trials.
Our findings are consistent with the literature. The
estimation of the causal effect of a treatment in an
observational study suffers from the same confounding
issue. Lepage et al.25 found that when treatment assign-
ment was driven by baseline variables only the
ANCOVA approach was unbiased for the average
treatment effect. A change score approach was again
found to be suffering from bias when baseline measures
predicted subsequent change. Finally in line with the
study by Vandenberghe et al.,26 we found that for con-
tinuous mediators and outcomes results were robust
against misspecification of the mediator model.
For simplicity, we have here assumed no interactions
between baseline variables and treatment allocation
and no interaction between the mediator and the
treatment in the model for the clinical outcome (moder-
ated mediation). However, we anticipate that the bias
results also hold under more complex data generating
models. The ANCOVA approach to mediation analysis
can be generalised to situations in which there is treat-
ment moderation by including relevant interaction
terms in the models.27–29 In practice, any ‘no interac-
tion assumption’ should be verified before proceeding
to use the simpler ANCOVA approach.
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